Document ID: NEHTA-2370:2016

Clinical Terminology - SNOMED CT-AU v20160630

Release Note

30 June 2016

Approved for external information

Summary

EP-2367:2016 Clinical Terminology v20160630

SNOMED CT-AU is the Australian extension to the Systematized Nomenclature of Medicine, Clinical Terms (SNOMED CT®[1]), incorporating all Australian-developed terminology including the Australian Medicines Terminology (AMT) along with the core international data. SNOMED CT-AU provides additional content, local variations and customisations of terms relevant to the Australian healthcare sector for implementation in Australian clinical IT systems.

All terminology files are prepared in a format and to a standard that is consistent with International Health Terminology Standards Development Organisation (IHTSDO) releases. For the convenience of AMT-only users, these release files are currently also available as a stand-alone download; however a separate release note has not been provided.

Release rationale

Each month, NEHTA releases clinical terminology updates to incorporate new content, enhance existing content, and make more effective use of the existing terminology.

This release is maintained against the January 2016 SNOMED CT release from the IHTSDO. It also incorporates AMT products that become available on the *Schedule of Pharmaceutical Benefits* – including the *Repatriation Pharmaceutical Benefits Schedule* – on or before 1 July 2016.

Identifying the version of this release of SNOMED CT-AU

Since November 2015, the AMT has been included as a formal subset of the SNOMED CT-AU release. This has the dual effect of enabling future integration work, and to better support the usage of terminology within the My Health Record system. Both terminologies use the same module identifier.

When using codes from this release (for example, in clinical documents, maps, or terminology servers) the following string should be used to identify the version of this release:

http://snomed.info/sct/32506021000036107/version/20160630

[1] This material includes SNOMED Clinical Terms™ (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO). All rights reserved. SNOMED CT® was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO.

Package inclusions

New

Identifier	Name and version
NEHTA-2370:2016	*Clinical Terminology - SNOMED CT-AU – Release Note v20160630*
NEHTA-2369:2016	*SNOMED CT-AU – Combined Release File v20160630*
NEHTA-2368:2016	*Australian Medicines Terminology – Data Extract v20160630*

Audience

The audience for this end product is any licence holder with a practical interest in SNOMED CT-AU or AMT release files, including: software developers, content or mapping developers, testers, information system suppliers, analysts, terminology or classification specialists, health IT professionals and researchers.

Change summary

Content

Terminology	Category	Description
SCT-AU	Requested content	Request submissions for new concepts, descriptions and changes to Preferred Terms within the *Australian dialect reference set* have been processed for this release. In particular, work has been undertaken on requests for the Princess Alexandra Hospital, Queensland Health SurgiNet project, and the Royal Australian College of Surgeons.
SCT-AU	New content reference sets	The following reference sets have been added to the release: • *Dose instruction verb reference set* • *Dose route and form extended association reference set*
AMT	Clinical Interface Descriptions	Both Fully Specified Names (FSNs) and Preferred Terms (PTs) for AMT product concepts referencing the following dose forms have been amended in this release as part of the Clinical Interface Descriptions project. The amendment to remove the colon and inversion was performed as a minor description edit, therefore there are no changes to any concept or description IDs: • "tablet: effervescent" to "effervescent tablet" (195 concepts); • "gum: chewing" to "chewing gum" (248 concepts); • "tablet: chewable" to "chewable tablet" (448 concepts); • "tablet: enteric" to "enteric tablet" (1052 concepts); • "capsule: modified release" to "modified release capsule" (730 concepts); • "tablet: orally disintegrating" to "orally disintegrating tablet" (512 concepts) "oral liquid: suspension" to "oral suspension" (542 concepts) "granules: effervescent" to "effervescent granules" (28 concepts); • "injection: subcutaneous infusion" to "subcutaneous infusion injection" (6 concepts);

Terminology	Category	Description
		• "oral liquid: for freezing" to "oral liquid for freezing" (12 concepts); • "patch: dermal" to "dermal patch" (20 concepts); • "roll: wrapped pack" to "wrapped pack roll" (11 concepts); and • "spray: pressurised" to "pressurised spray" (31 concepts).
AMT	Data maintenance (AMT-11313)	The Trade Products of Memantine Hydrochloride (Generic Health) Memantine Hydrochloride (Apo), and Memantine Hydrochloride (RBX) have been amended to remove the modified base status, to align with AMT editorial rules. The affected products are: • Memantine Hydrochloride (Generic Health) 10 mg tablet: film-coated, 56, blister pack; • Memantine Hydrochloride (Generic Health) 20 mg tablet: film-coated, 14, blister pack; • Memantine Hydrochloride (Generic Health) 20 mg tablet: film-coated, 28, blister pack; • Memantine Hydrochloride (Generic Health) 20 mg tablet: film-coated, 42, blister pack; • Memantine Hydrochloride (Generic Health) 20 mg tablet: film-coated, 56, blister pack; Memantine Hydrochloride (Apo) 10 mg tablet: film-coated, 14, bottle; • Memantine Hydrochloride (Apo) 10 mg tablet: film-coated, 30, bottle; • Memantine Hydrochloride (Apo) 10 mg tablet: film-coated, 50, bottle; • Memantine Hydrochloride (Apo) 10 mg tablet: film-coated, 56, bottle; • Memantine Hydrochloride (Apo) 10 mg tablet: film-coated, 1000, bottle; • Memantine Hydrochloride (Apo) 10 mg tablet: film-coated, 14, blister pack; • Memantine Hydrochloride (Apo) 10 mg tablet: film-coated, 30, blister pack; • Memantine Hydrochloride (Apo) 10 mg tablet: film-coated, 50, blister pack; • Memantine Hydrochloride (Apo) 10 mg tablet: film-coated, 56, blister pack; • Memantine Hydrochloride (Apo) 10 mg tablet: film-coated, 100, blister pack; • Memantine Hydrochloride (Apo) 20 mg tablet: film-coated, 28, blister pack; • Memantine Hydrochloride (RBX) 20 mg tablet: film-coated, 28, blister pack; and • Memantine Hydrochloride (RBX) 10 mg tablet: film-coated, 56, blister pack. Which will be replaced with the follow descriptions: • Memantine (Generic Health) 10 mg tablet: film-coated, 56, blister pack;

Terminology	Category	Description
		• Memantine (Generic Health) 20 mg tablet: film-coated, 14, blister pack; • Memantine (Generic Health) 20 mg tablet: film-coated, 28, blister pack; • Memantine (Generic Health) 20 mg tablet: film-coated, 42, blister pack; • Memantine (Generic Health) 20 mg tablet: film-coated, 56, blister pack ;Memantine (Apo) 10 mg tablet: film-coated, 14, bottle; • Memantine (Apo) 10 mg tablet: film-coated, 30, bottle; • Memantine (Apo) 10 mg tablet: film-coated, 50, bottle; • Memantine (Apo) 10 mg tablet: film-coated, 56, bottle; • Memantine (Apo) 10 mg tablet: film-coated, 1000, bottle; • Memantine (Apo) 10 mg tablet: film-coated, 14, blister pack; • Memantine (Apo) 10 mg tablet: film-coated, 30, blister pack; • Memantine (Apo) 10 mg tablet: film-coated, 50, blister pack; • Memantine (Apo) 10 mg tablet: film-coated, 56, blister pack; • Memantine (Apo) 10 mg tablet: film-coated, 100, blister pack; • Memantine (Apo) 20 mg tablet: film-coated, 28, blister pack; • Memantine (RBX) 20 mg tablet: film-coated, 28, blister pack; and • Memantine (RBX) 10 mg tablet: film-coated, 56, blister pack.
AMT	Data maintenance (AMT-10849)	The strength representation of Flebogamma 5% DIF 5% (2.5 g/50 mL) injection: solution, 50 mL vial has been amended from "5% (2.5 g/50 mL)" to "2.5 g/50 mL".
AMT	Data maintenance (AMT-11768)	The Trade Product name for "Orabase Protective Paste" has been amended to "Orabase Protective", and its dose form has been amended from "oromucosal paste" to "paste".
AMT	Data maintenance (AMT-10089)	The product Ringworm 1% ointment, 15 g, tube has been amended to include sponsor details as part of its Trade Product name - "Ringworm (Amneal)".
AMT	Data maintenance (AMT-11100)	The dose form for the product Fluoxebell 20 mg capsule, 28, blister pack has been amended from "capsule" to the specific (trade) dose form "capsule: hard".
AMT	Data maintenance (AMT-12150)	The strength representation for potassium has been amended from potassium chloride 1.015 g to potassium chloride 1.015 g (potassium 14.2 mmol), to show that amount of potassium in mmol). The affected products are: • Moviprep Lemon powder for oral liquid, 4 sachets; and • Moviprep Orange powder for oral liquid, 4 sachets.

Terminology	Category	Description
AMT	Data maintenance (AMT-11793)	The dose form for the "Cardiprin dispersible tablet" and "Disprin dispersible tablet" product ranges has been amended from "dispersible tablet" to "tablet". The affected products are: • Cardiprin 100 mg dispersible tablet, 30, blister pack; • Cardiprin 100 mg dispersible tablet, 90, blister pack; • Cardiprin 100 mg dispersible tablet, 100, blister pack; • Cardiprin 100 mg dispersible tablet, 180, blister pack; • Disprin Forte dispersible tablet, 24, strip pack; • Disprin Original 300 mg dispersible tablet, 96, strip pack; • Disprin Original 300 mg dispersible tablet, 24, strip pack; • Disprin Original 300 mg dispersible tablet, 48, strip pack; • Disprin Original 300 mg dispersible tablet, 6, strip pack; • Disprin Max 500 mg dispersible tablet, 16, strip pack; and • Disprin Max 500 mg dispersible tablet, 6, strip pack. Which will be replaced by the following descriptions: • Cardiprin 100 mg tablet, 30, blister pack; • Cardiprin 100 mg tablet, 90, blister pack; • Cardiprin 100 mg tablet, 100, blister pack; • Cardiprin 100 mg tablet, 180, blister pack; • Disprin Forte tablet, 24, strip pack; • Disprin Original 300 mg tablet, 96, strip pack; • Disprin Original 300 mg tablet, 24, strip pack; • Disprin Original 300 mg tablet, 48, strip pack; • Disprin Original 300 mg tablet, 6, strip pack; • Disprin Max 500 mg tablet, 16, strip pack; and • Disprin Max 500 mg tablet, 6, strip pack.
AMT	Data maintenance (AMT-11989)	The strength representation of Azep 140 microgram/actuation nasal spray product range has been amended from 140 microgram/actuation to 0.1%. The container type has also been amended from "pump actuated metered dose aerosol" to "pump pack" The affected products are: • Azep 140 microgram/actuation nasal spray, 5 mL, pump actuated metered dose aerosol; • Azep 140 microgram/actuation nasal spray, 10 mL, pump actuated metered dose aerosol; and • Azep 140 microgram/actuation nasal spray, 20 mL, pump actuated metered dose aerosol. Which will be replaced by the following descriptions: • Azep 0.1% nasal spray, 5 mL, pump pack; • Azep 0.1% nasal spray, 10 mL, pump pack; and • Azep 0.1% nasal spray, 20 mL, pump pack.

Terminology	Category	Description
AMT	Data maintenance (AMT-2907)	The dose form for the Irbesartan (APO) product range has been amended from "tablet" to the specific (trade) dose form "tablet: film coated". The affected products are: • Irbesartan (Apo) 75 mg tablet, 30, blister pack; • Irbesartan (Apo) 150 mg tablet, 30, blister pack; • Irbesartan (Apo) 300 mg tablet, 30, blister pack; • Irbesartan (Apo) 75 mg tablet, 30, bottle; • Irbesartan (Apo) 150 mg tablet, 30, bottle; and • Irbesartan (Apo) 300 mg tablet, 30, bottle . Which will be replaced by the following descriptions: • Irbesartan (Apo) 75 mg tablet: film-coated, 30, blister pack; • Irbesartan (Apo) 150 mg tablet: film-coated, 30, blister pack; • Irbesartan (Apo) 300 mg tablet: film-coated, 30, blister pack; • Irbesartan (Apo) 75 mg tablet: film-coated, 30, bottle; • Irbesartan (Apo) 150 mg tablet: film-coated, 30, bottle; and • Irbesartan (Apo) 300 mg tablet: film-coated, 30, bottle.

Terminology	Category	Description
AMT	Data maintenance (AMT-412)	The following products are being remodelled to amend the Intended Active Ingredient (IAI), Basis of Strength Substance (BoSS), and the Trade Product name: • Actonel Combi D (4 x 35 mg tablets, 24 x sachets), 1 pack, composite pack; • Actonel EC Combi D (4 x Once-a-Week tablets, 24 x Calcium carbonate / colecalciferol (Sanofi-Aventis) sachets), 1 pack, composite pack; • Actonel EC Combi D (1 x Once-a-Week tablet, 6 x Calcium carbonate / colecalciferol (Sanofi-Aventis) sachets), 1 pack, composite pack; • Calcium carbonate / colecalciferol (Sanofi-Aventis) granules: effervescent, 24 sachets; • Calcium carbonate / colecalciferol (Sanofi-Aventis) granules: effervescent, 6 sachets; • Calcium carbonate / colecalciferol (Winthrop) granules: effervescent, 24 sachets; and • Risedronate Sodium EC Combi D (Winthrop) (4 x Risedronate Sodium tablets, 24 x Calcium carbonate / colecalciferol sachets), 1 pack, composite pack Which will be replaced by the following descriptions: • Actonel Combi D (4 x Actonel Once-a-Week tablets, 24 x Actonel Combi D sachets), 1 pack, composite pack • Actonel EC Combi D (4 x Actonel EC Once-a-Week tablets, 24 x Actonel EC Combi D sachets), 1 pack, composite pack • Actonel EC Combi D (1 x Actonel EC Once-a-Week tablet, 6 x Actonel EC Combi D sachets), 1 pack, composite pack • Actonel Combi D effervescent granules, 24 sachets • Actonel EC Combi D effervescent granules, 6 sachets • Risedronate Sodium EC Combi D (Winthrop) effervescent granules, 24 sachets • Risedronate Sodium EC Combi D (Winthrop) (4 x Risedronate EC tablets, 24 x Risedronate EC Combi D sachets), 1 pack, composite pack The remodelling will reflect calcium as the IAI, calcium carbonate as the BoSS with an OSR representing calcium, and amendments to the Trade Product name to reflect current AMT editorial rules..
AMT	Data maintenance (AMT-12250)	The representation of calcium and calcium carbonate in the product "Calvid granules: effervescent, 30 x 7 g sachets" has been amended to reflect the IAI is calcium and the BoSS is calcium carbonate. The strength representation was also amended from "calcium (as carbonate) 1 g" to "calcium carbonate 2.5 g (calcium 1 g)".
AMT	Appendix C.6 Medicinal Product Preferred Term sequence of ingredients (AMT-7507	Multi-ingredient products have been reviewed and work has continued on the ordering of ingredients within the FSN and PT. Ingredients in the FSN are ordered alphabetically, whereas ingredients in the PT are based on the order of the innovator product. All subsequent products with the same combination of ingredients will follow the order of the innovator product.

Terminology	Category	Description
	and AMT- 7500)	Ingredient orders that have been amended this month include: • brompheniramine + dextromethorphan + phenylephrine; • bufexamac + miconazole; • butoxyethyl nicotinate + nonivamide; • butyl hydroxybenzoate + salicylic acid + propionic acid; • caffeine + dimenhydrinate + hyoscine hydrobromide trihydrate; • cajuput oil + camphor + clove bud oil + menthol + mint oil dementholised; • camphor + eucalyptus oil + menthol; • camphor + eucalyptus oil + menthol + methyl salicylate; and • camphor + eucalyptus oil + menthyl valerate + quinine. Which have been reordered to: • brompheniramine + phenylephrine + dextromethorphan; • miconazole + bufexamac; • nonivamide + butoxyethyl nicotinate; • salicylic acid + butyl hydroxybenzoate + propionic acid; • dimenhydrinate + hyoscine hydrobromide trihydrate + caffeine; • camphor + menthol + cajuput oil + mint oil dementholised + clove but oil; • menthol + camphor + eucalyptus oil; • methyl salicylate + camphor + menthol + eucalyptus oil; and • menthyl valerate + quinine + camphor + eucalyptus oil.
AMT	Data maintenance (AMT-11757)	The medicinal dose form for Antabuse 200 mg tablet: effervescent, 30, bottle is tablet. As its specific dose form, tablet: effervescent, is a significant dose form, the medicinal dose form has been amended to tablet: effervescent. This will be reflected in the MPUU and MPP: • disulfiram 200 mg effervescent tablet; and • disulfiram 200 mg effervescent tablet, 30.

Future changes

Terminology	Category	Description
AMT	Clinical Interface Descriptions	A work plan has been developed to amend Fully Specified Names and Preferred Terms for AMT product concepts referencing dose forms containing inversion, for example, "tablet: modified release". Inversion will be removed, resulting in "modified release tablet" for this example. These amendments are being implemented over a period of several months. See the **Content** table above for the details of this month's changes. The following proposed changes are planned over the next releases: • "inhalation: solution" to "inhalation solution";

Terminology	Category	Description
		• "inhalation: powder for" to "powder for inhalation"; • "strip: diagnostic" to "diagnostic strip"; • "injection: powder for" to "powder for injection"; • "injection: concentrated" to "concentrated injection"; • "solution: irrigation" to "irrigation solution"; • "injection: suspension" to "injection suspension"; • "capsule: hard" to "hard capsule"; • "capsule: soft" to "soft capsule"; • "eye drops: solution" to "eye drops solution"; • "injection: intravenous infusion" to "intravenous infusion injection"; • "injection: solution" to "injection solution"; • "oral liquid: solution" to "oral liquid solution"; • "tablet: film-coated" to "film-coated tablet"; and • "tablet: uncoated" to "uncoated tablet".
SCT-AU & AMT	Dose-based prescribing	Additional terminology, reference sets and product relationships to support dose-based ordering are currently being developed for release during 2016 to further extend the usability of the AMT within acute care settings.

AMT concept counts

The figures quoted here have been extracted from the notable concept reference sets and include both active and inactive concepts. See the *AMT v3 Development Approach for Reference Sets*[2] for information about these reference sets and their members.

Concept	Current count	Changes since the last release
Medicinal Product (MP)	1987	16
Medicinal Product Unit of Use (MPUU)	5414	46
Medicinal Product Pack (MPP)	9961	187
Trade Product (TP)	7609	75
Trade Product Unit of Use (TPUU)	13157	172
Trade Product Pack (TPP)	20134	419
Containered Trade Product Pack (CTPP)	21374	455
Total	79636	1370

[2] Available at http://www.nehta.gov.au/implementation-resources/ehealth-foundations/australian-medicines-terminology-common.

Supporting documentation

Supporting documentation and guidance for both SNOMED CT-AU and the AMT is available from the SNOMED CT-AU Common[3] and Australian Medicines Terminology v3 Model - Common[4] pages on the NEHTA website, most notably:

- *NCTIS - Reference Set Library v2.3;*
- *NCTIS - Development Approach for Reference Sets v2.3;*
- *NCTIS - Adverse Reactions Reference Set Implementation Guide v1.0; and*
- *NCTS – Australian Technical Implementation Guide v1.0.*

The release notes associated with each of these end product web pages contain recommended reading guides for different audiences.

IHTSDO documentation

The SNOMED CT® Document Library[5] on the IHTSDO website includes a number of resources that are relevant to SNOMED CT-AU developers, most notably the *SNOMED CT Technical Implementation Guide*. This document provides specifications of release files and other IHTSDO standards, accompanied by SNOMED CT implementation guidance.

Terminology viewers

NEHTA recommends that users access SNOMED CT-AU and AMT content via the SHRIMP application[6], which is an online browser available at http://ontoserver.csiro.au/shrimp.[7] You can search for SNOMED CT-AU and AMT content or browse the hierarchies by selecting the latest version of "SNOMED Clinical Terms Australian Extension" in the dropdown menu. Earlier versions of the AMT (prior to November 2015) can be searched by selecting "Australian Medicines Terminology".

Alternatively, the Minnow application[8] (available as a free download at http://aehrc.com/minnow) can be also be used to access these terminologies.

IHTSDO browser

The IHTSDO has an online browser that allows searching and browsing of the SNOMED CT International Edition and SNOMED CT-AU, along with a number of other national extensions provided by other IHTSDO member countries. The browser is available from http://browser.ihtsdotools.org.

NEHTA makes no guarantees regarding the functionality or update cycle for this browser.

Known issues

Data issues

Data issues listed in this release note are limited to only those that affect the accuracy of the concept description. Issues are identified and tracked in the following way:

- The ID number is an internal identifier within the NEHTA issue management system.

[3] https://www.nehta.gov.au/implementation-resources/ehealth-foundations/snomed-ct-au-common
[4] See footnote 2.
[5] See https://confluence.ihtsdotools.org/display/DOC.
[6] Shrimp was developed by the Australian e-Health Research Centre (AEHRC).
[7] An online help tour of SHRIMP is available at http://ontoserver.csiro.au/shrimp?help.
[8] Minnow was developed by the Australian e-Health Research Centre (AEHRC).

- For AMT products, the Therapeutic Goods Administration (TGA) Label Name and registration number (ARTG or Licence ID) are generally used. In cases where the medicinal product is not registered by the TGA, a NEHTA identifier has been included.

Terminology	ID	Known issues
AMT	AMT-2313	Due to an issue identified in the v2 to v3 transform where the Unit of Use Quantity appears as "24 x 100mL packs" rather than "24 x 2 bag packs" the Medicinal Product Pack (MPP), Trade Product Pack (TPP), and Containered Trade Product Pack (CTPP) descriptions for the following products will be amended in a future release: • ARTG 48515 Sodium Chloride (Baxter) 0.9% (900 mg/100 mL) injection: intravenous infusion, 24 x 100 mL packs, bag; • ARTG 48515 Sodium Chloride (Baxter) 0.9% (900 mg/100 mL) injection: intravenous infusion, 100 mL pack, bag; • ARTG 48525 Glucose (Baxter) 5% (5 g/100 mL) injection: intravenous infusion, 24 x 100 mL packs, bag; and • ARTG 48525 Glucose (Baxter) 5% (5 g/100 mL) injection: intravenous infusion, 100 mL pack, bag.
AMT	LIN-674	In AMT v2 the manufacturer's code for suppliers, such as Baxter, is placed at the end of the Containered Trade Product Pack (CTPP) PT descriptions. This code currently does not get added to the CTPP descriptions in v3 and it is anticipated the code will be added to the AMT v3 descriptions in a future release.

AMT modelling issues

As a result of re-modelling the AMT from v2 to v3, there currently exist some Medicinal Product Unit of Use (MPUU) concepts in the data where the Fully Specified Name (FSN) terms or modelling may seem ambiguous. This can occur when the Basis of Strength Substance (BoSS) is different to the Pharmaceutical Ingredient (PI). For example, the MPUU FSN may include "amoxycillin" (representing the BoSS) while the actual substance present is amoxycillin trihydrate (representing the PI).

The AMT model is being continually developed and refined. This issue will be examined as a part of these ongoing processes.

AMT editorial rule deviations

The following rules are in the process of implementation or have yet to be implemented. The identifiers provided below align with those in the *AMT v3 Model Editorial Rules*.[9]

Preferred Term (PT) descriptions

Currently, some AMT descriptions may differ slightly when compared with those expected from the relevant editorial rules; this is due to the automated process used in authoring the terminology. In most cases, additional information has been added to the descriptions beyond the stated editorial rules. AMT v3 implementers are advised to contact the National Clinical Terminology and Information Service (NCTIS) via help@nehta.gov.au if they have any concerns about this issue. Details of any existing deviations are documented below.

[9] See footnote 2.

Item	Description
AMT-APP-STR-10	Where the strength or volume of a product is not a set single value but may vary within a given range, the strength or volume will be expressed as the range, with the lower numerical value, followed by the word "to" and then the upper numerical value and the relevant units.
AMT-APP-STR-11	Where the strength or volume of a product is expressed with a lower limit only (that is, "contains not less than", "contains equal to or greater than", or "more than") the strength or volume will be expressed with the word "minimum" followed by the relevant strength or volume.
Appendix C.4 Waters of hydration	Waters of hydration shall only be expressed for each ingredient in the FSN where hydration is present and the modification is deemed to be clinically significant (according to Appendix B). Where an ingredient is found to be anhydrous or dried, this shall not be expressed. Note that waters of hydration shall only be expressed in the PT if they are part of the proprietary name. There are some known deviations from this rule in the descriptions and the NCTIS is working to rectify them over time.
Appendix C.6 Medicinal Product Preferred Term sequence of ingredients	Ingredients will be sequenced in alphabetical order within the FSN. For multi-ingredient products, the order of the ingredients in the PT will be based on the order used by the innovator product. All subsequent products with the same combination of ingredients will follow the order of the innovator product. Note that some ongoing anomalies exist in the PT order and are being rectified over time.
Appendix K.1 Strength expressions for vaccines	Strength will be represented as part of the FSN but will not be included in PTs for vaccines. Where two products exist with different amounts of antigen intended for different populations, a term describing the population, rather than strength, will be included in the MPUU.

Divergence from the SNOMED CT Editorial Guide

According to the *SNOMED CT Editorial Guide*[10], minor changes to the Fully Specified Name (FSN) that do not alter the meaning of the concept are allowed. Any concept with a minor change does not need to be retired, however the FSN description will be retired and a new replacement term string created with a new unique identifier. There are instances in SNOMED CT releases where this has not occurred – minor changes generated a new version of the FSN without any corresponding changes to the unique identifier. Although the NCTIS is currently seeking to clarify this rule with the IHTSDO, it will continue to create a new version of the FSN when minor changes are required.

Similarly, the NCTIS will create a new version of the PT in those instances where a minor change results in a new version of the description being created.

[10] Available from https://confluence.ihtsdotools.org/display/DOC

Implementation guidance

All terminology concepts have an FSN, which is intended to provide an unambiguous name for the concept, and a PT, which is intended to capture the common words or phrases used by Australian clinicians. System developers and end users should only implement PTs for clinical use, as these are the concepts developed for use by clinicians in Australia.

The NCTIS provides documentation specific to the Australian Medicines Terminology release and SNOMED CT-AU, which can be downloaded from the NEHTA eHealth Foundations page.[11] Users may also benefit from referring to documentation provided with the SNOMED CT International terminology releases.

Safety guidance

NEHTA applies its clinical safety management system to SNOMED CT-AU and AMT development cycles and reported incidents. This is to minimise the potential for clinical safety hazards to be introduced during the development of terminology.

Implementers are required to undertake their own risk assessment and management in the context of their own implementations of the AMT. In addition, it is expected that implementers will contact NEHTA's Product Support team with any questions or concerns.

The terminology may be applied within a variety of use cases. NEHTA recommends that all licence holders planning on either developing a map or undertaking an implementation contact the NCTIS to discuss their intended uses.[12] This notification will allow Product Support Services to be made available as appropriate.

Please note that if licence holders become aware of any errors or omissions during their development, they are obliged to notify NEHTA, as per clause 2.5 of the *Australian National Terminology Licence Agreement*, which states:

"*If the Licensee becomes aware of any material error or change or correction needed in either the National Release or the International Release, the Licensee agrees to advise NEHTA promptly of such error, change or correction by following NEHTA's procedures for change notification that NEHTA prescribes and notifies to the Licensee from time to time.*"[13]

To report an error, please email help@nehta.gov.au.

Product support services

The NCTIS has a dedicated Product Support team to assist licence holders in their understanding and implementation of SNOMED CT-AU. Support services can be tailored to customer requirements, and range from general training and education on the terminology through to specific technical support. The following support channels are freely available:

- downloadable resources from the NEHTA eHealth Foundations page;
- email and phone support;
- webinars;
- technical workshops; and
- individual technical support at your workplace.

[11] Available from https://www.nehta.gov.au/implementation-resources/ehealth-foundations.
[12] The NCTIS can be contacted via help@nehta.gov.au.
[13] http://www.nehta.gov.au/our-work/clinical-terminology/registering-for-a-license/license-agreements

To request support, or to provide any other feedback, please email help@nehta.gov.au or phone 1300 901 001.

Hosting reference sets developed and owned by third parties

The NCTIS has initiated a service whereby reference sets that are developed and owned by licence holders can be released as part of SNOMED CT-AU. The ownership and future development of the reference sets are intended to be continued by the licence holders, and content will be released in a dedicated module within SNOMED CT-AU to indicate this. For more information, or to express interest in submitting a reference set, please contact help@nehta.gov.au.

How to request changes to our terminology products

The NCTIS is committed to the refinement and improvement of its terminology products, and contributing to the refinement and improvement of SNOMED CT. In keeping with these commitments, we welcome requests for changes to existing content or new content additions. A form for submitting such requests is available from the SNOMED CT-AU area of the NEHTA website.[14]

Previous releases

SNOMED CT-AU and the AMT are released monthly in a combined Clinical Terminology release. Links to the previous six months of combined releases are provided below, along with the final uncombined SNOMED CT-AU and AMT releases. Links to earlier versions are still available for download from the NEHTA website

Date	Version
31 May 2016	EP-2333-2016 Clinical Terminology v20160531
31 April 2016	EP-2301-2016 Clinical Terminology v20160430
31 March 2016	EP-2268-2016 Clinical Terminology v20160331
29 February 2016	EP-2233:2016 Clinical Terminology v20160229
31 January 2016	EP-2227:2016 Clinical Terminology v20160131
31 December 2015	EP-2202:2015 Clinical Terminology v20151231
31 October 2015	EP-2168:2015 AMT v20151031 The last uncombined AMT release.
31 May 2015	EP-2066:2015 SNOMED CT-AU v20150531 The last uncombined SNOMED CT-AU release.

[14] http://www.nehta.gov.au/our-work/clinical-terminology/snomed-clinical-terms/request-submission-product-content-changes

Publication date: 30 June 2016

Contact for enquiries
Telephone: 1300 901 001 or email: help@nehta.gov.au

Acknowledgements

Council of Australian Governments

The National E-Health Transition Authority is jointly funded by the Australian Government and all State and Territory Governments.

IHTSDO (SNOMED CT)

This material includes SNOMED Clinical Terms™ (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO). All rights reserved. SNOMED CT® was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO, (http://www.ihtsdo.org/).